WO2009025080A1 - 大腸癌マーカポリペプチド、及び大腸癌の診断方法 - Google Patents

大腸癌マーカポリペプチド、及び大腸癌の診断方法 Download PDF

Info

Publication number
WO2009025080A1
WO2009025080A1 PCT/JP2008/002217 JP2008002217W WO2009025080A1 WO 2009025080 A1 WO2009025080 A1 WO 2009025080A1 JP 2008002217 W JP2008002217 W JP 2008002217W WO 2009025080 A1 WO2009025080 A1 WO 2009025080A1
Authority
WO
WIPO (PCT)
Prior art keywords
colorectal cancer
marker polypeptide
cancer marker
diagnosis
seq
Prior art date
Application number
PCT/JP2008/002217
Other languages
English (en)
French (fr)
Inventor
Yoshio Kodera
Tadakazu Maeda
Yusuke Kawashima
Fumio Nomura
Takeshi Tomonaga
Original Assignee
School Juridical Person Kitasato Institute
National University Corporation Chiba University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Juridical Person Kitasato Institute, National University Corporation Chiba University filed Critical School Juridical Person Kitasato Institute
Priority to JP2009528951A priority Critical patent/JP5570810B2/ja
Publication of WO2009025080A1 publication Critical patent/WO2009025080A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

　【課題】　体液試料、特に血清等に存在する大腸癌マーカポリペプチド、及び該大腸癌マーカを検出する大腸癌の診断方法を提供する。 　　【解決手段】　配列番号１、２、３、及び５のいずれか１のアミノ酸配列を含む大腸癌マーカポリペプチド；並びに配列番号１、２、３、及び５のいずれか１のアミノ酸配列を含む、大腸癌マーカポリペプチドの少なくとも１種を、被験者から得た体液試料から検出することを特徴とする、大腸癌の診断方法である。 　　
PCT/JP2008/002217 2007-08-18 2008-08-15 大腸癌マーカポリペプチド、及び大腸癌の診断方法 WO2009025080A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528951A JP5570810B2 (ja) 2007-08-18 2008-08-15 大腸癌マーカポリペプチド、及び大腸癌の診断方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007213211 2007-08-18
JP2007-213211 2007-08-18

Publications (1)

Publication Number Publication Date
WO2009025080A1 true WO2009025080A1 (ja) 2009-02-26

Family

ID=40377989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002217 WO2009025080A1 (ja) 2007-08-18 2008-08-15 大腸癌マーカポリペプチド、及び大腸癌の診断方法

Country Status (2)

Country Link
JP (1) JP5570810B2 (ja)
WO (1) WO2009025080A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150517A3 (en) * 2010-06-01 2012-01-26 Miraculins, Inc. Xyxin fragment biomarker for diagnosis of colon cancer
JP2015108515A (ja) * 2013-12-03 2015-06-11 株式会社プロトセラ 大腸癌の診断のための検査方法
JP2016148623A (ja) * 2015-02-13 2016-08-18 京都府公立大学法人 大腸がんの検出方法
WO2024203701A1 (ja) * 2023-03-30 2024-10-03 国立大学法人東海国立大学機構 情報処理装置、情報処理方法、および、コンピュータプログラム

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020583A2 (en) * 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004090550A2 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2006053592A1 (en) * 2004-08-13 2006-05-26 Indivumed Gmbh Use of c3a and derivatives thereof as a biomarker for colorectal ademona and/or carcinoma; diagnosis method and test system using the same
WO2006125021A2 (en) * 2005-05-16 2006-11-23 Dana Farber Cancer Institute, Inc. Fibrinogen alpha and hemoglobin polypeptides as cancer markers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020583A2 (en) * 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004090550A2 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2006053592A1 (en) * 2004-08-13 2006-05-26 Indivumed Gmbh Use of c3a and derivatives thereof as a biomarker for colorectal ademona and/or carcinoma; diagnosis method and test system using the same
WO2006125021A2 (en) * 2005-05-16 2006-11-23 Dana Farber Cancer Institute, Inc. Fibrinogen alpha and hemoglobin polypeptides as cancer markers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KODERA YOSHIO ET AL.: "Daichogan no peptide shuyo marker no kaihatsu", THE JAPANESE CANCER ASSOCIATION GAKUJUTSU SOKAI KIJI, vol. 66TH, 25 August 2007 (2007-08-25), pages 88 - 89 *
KOOMEN M.JOHN ET AL.: "Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 19, 2005, pages 1624 - 1636 *
WARD D.G. ET AL.: "Identification of serum biomarkers for colon by proteomic analysis", BRITISH JOURNAL OF CANCER, vol. 94, 2006, pages 1898 - 1905 *
ZHENG G.X. ET AL.: "Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF MS", EXP.ONCOL., vol. 28, no. 4, 2006, pages 282 - 287 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150517A3 (en) * 2010-06-01 2012-01-26 Miraculins, Inc. Xyxin fragment biomarker for diagnosis of colon cancer
EP2576610A2 (en) * 2010-06-01 2013-04-10 Miraculins Inc. Biomarker for diagnosis and treatment of colorectal cancer
EP2576610A4 (en) * 2010-06-01 2014-03-05 Miraculins Inc BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF DARM CANCER
JP2015108515A (ja) * 2013-12-03 2015-06-11 株式会社プロトセラ 大腸癌の診断のための検査方法
JP2016148623A (ja) * 2015-02-13 2016-08-18 京都府公立大学法人 大腸がんの検出方法
WO2024203701A1 (ja) * 2023-03-30 2024-10-03 国立大学法人東海国立大学機構 情報処理装置、情報処理方法、および、コンピュータプログラム

Also Published As

Publication number Publication date
JP5570810B2 (ja) 2014-08-13
JPWO2009025080A1 (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
TW200745556A (en) Biomarkers for liver fibrotic injury
EP3070097A3 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
WO2005072049A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
NZ601590A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2007092627A3 (en) Detection of cancer by elevated levels of bcl-2
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2010041892A3 (ko) Aimp1 폴리펩티드의 신규한 용도
WO2009057294A1 (ja) 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
WO2009111470A3 (en) Protease assay
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2010041046A8 (en) Granin proteins as markers of heart disease
EP2520935A3 (en) Organ-specific proteins and methods of their use
CA2798562A1 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
WO2009004822A1 (ja) 抗Muc17抗体
EP2339022A3 (en) Use of methylated or unmethylated line-1 DNA as a cancer marker
HRP20231525T1 (hr) Postupci i pripravci za dijagnozu i liječenje raka
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008012362A3 (en) New protein isoforms and uses thereof
PL2021794T3 (pl) Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
WO2012012802A3 (en) Neoepitope detection of disease using protein arrays
WO2009126969A3 (en) Biomarkers for endometrial disease
WO2007132120A3 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2009025080A1 (ja) 大腸癌マーカポリペプチド、及び大腸癌の診断方法
WO2007023191A3 (de) Polypeptidmarker zur diagnose von blasenkrebs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827705

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009528951

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827705

Country of ref document: EP

Kind code of ref document: A1